Greenwich LifeSciences: FLAMINGO-01 Open Label Immune Response Data Update
STAFFORD, Texas, April 02, 2025 – Greenwich LifeSciences, Inc. (GLSI), a clinical-stage biopharmaceutical company, recently announced an update on the ongoing Phase III clinical trial, FLAMINGO-01. This trial focuses on evaluating the efficacy of GLSI-100, an immunotherapy designed to prevent breast cancer recurrences.
FLAMINGO-01 Trial Overview
FLAMINGO-01 is a multicenter, open-label, single-arm trial designed to assess the safety, tolerability, and efficacy of GLSI-100 in patients with high-risk, early-stage breast cancer. The trial includes approximately 150 patients who have completed their primary therapy and are at increased risk of recurrence.
Immune Response Data
The Company reported that the immune response data from the first 100 patients enrolled in the trial showed encouraging results. The data indicates that GLSI-100 is stimulating an immune response in the majority of patients. Specifically, the data reveals:
- 95% of patients showed evidence of a systemic immune response
- 75% of patients had a significant increase in immune cell populations
- No dose-limiting toxicities or serious adverse events related to GLSI-100 have been reported
Impact on Individuals
For individuals with early-stage breast cancer, this data offers hope for a potential preventative treatment option. The immune response data suggests that GLSI-100 may be effective in stimulating the body’s immune system to fight off cancer cells before they have a chance to recur. This could lead to improved long-term outcomes and a reduced need for additional treatments.
Impact on the World
If the FLAMINGO-01 trial proves successful, GLSI-100 could represent a significant advancement in breast cancer prevention. Breast cancer is the most common cancer among women worldwide, and preventing recurrences could save countless lives. Furthermore, the development of an effective preventative treatment could reduce the overall healthcare costs associated with breast cancer care.
Conclusion
Greenwich LifeSciences’ update on the FLAMINGO-01 open label immune response data offers promising insights into the potential of GLSI-100 as a preventative treatment for breast cancer recurrences. The data suggests that the immunotherapy is stimulating an immune response in the majority of patients and is well-tolerated. If the trial results remain consistent, GLSI-100 could represent a significant advancement in breast cancer care and prevention.
The impact of this development on individuals and the world could be substantial. For individuals with early-stage breast cancer, the availability of a preventative treatment could lead to improved long-term outcomes and reduced need for additional treatments. On a global scale, the development of an effective preventative treatment could save countless lives and reduce healthcare costs associated with breast cancer care.
